# Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma

> **NCT01711242** · PHASE2 · COMPLETED · sponsor: **xie congying** · enrollment: 208 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01711242
- **Lead sponsor:** xie congying
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2020-01
- **Final completion:** 2021-01
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711242, "Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01711242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*